These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28109056)

  • 1. Impact of completeness of revascularization in complex coronary artery disease as measured with the SYNTAX revascularization index: An SEEDS Substudy.
    Xu B; Bettinger N; Guan C; Redfors B; Yang Y; Li B; Han Y; Su X; Yuan Z; Généreux P
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):541-548. PubMed ID: 28109056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiographic and Clinical Outcomes After Everolimus-Eluting Stenting for Unprotected Left Main Disease and High Anatomic Coronary Complexity.
    Migliorini A; Valenti R; Parodi G; Vergara R; Buonamici P; Cerisano G; Carrabba N; Antoniucci D
    JACC Cardiovasc Interv; 2016 May; 9(10):1001-7. PubMed ID: 27198680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.
    Chen SL; Han YL; Zhang YJ; Ye F; Liu HW; Zhang JJ; Xu B; Jiang TM; Zhou YJ; Lv SZ
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1233-41. PubMed ID: 24239199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR-LEFT-MAIN and ISAR-LEFT-MAIN 2 randomized clinical trials.
    Xhepa E; Tada T; Kufner S; Ndrepepa G; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Cassese S; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):1-10. PubMed ID: 27515100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical and angiographic outcomes of percutanenous coronary intervention with everolimus-eluting stents for the treatment of cardiac allograft vasculopathy.
    Cheng R; Vanichsarn C; Patel JK; Currier J; Chang DH; Kittleson MM; Makkar R; Kobashigawa JA; Azarbal B
    Catheter Cardiovasc Interv; 2017 Jul; 90(1):48-55. PubMed ID: 27862865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 3-dimensional bifurcation angle on 5-year outcome of patients after percutaneous coronary intervention for left main coronary artery disease: a substudy of the SYNTAX trial (synergy between percutaneous coronary intervention with taxus and cardiac surgery).
    Girasis C; Farooq V; Diletti R; Muramatsu T; Bourantas CV; Onuma Y; Holmes DR; Feldman TE; Morel MA; van Es GA; Dawkins KD; Morice MC; Serruys PW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1250-60. PubMed ID: 24355115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index.
    Généreux P; Campos CM; Yadav M; Palmerini T; Caixeta A; Xu K; Francese DP; Dangas GD; Mehran R; Leon MB; Serruys PW; Stone GW
    EuroIntervention; 2015 Oct; 11(6):634-42. PubMed ID: 25308300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
    Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients.
    Piccolo R; Pilgrim T; Heg D; Franzone A; Rat-Wirtzler J; Räber L; Silber S; Serruys PW; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1657-66. PubMed ID: 26585615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the SYNTAX revascularization index to quantify reasonable level of incomplete revascularization after percutaneous coronary intervention.
    Généreux P; Campos CM; Farooq V; Bourantas CV; Mohr FW; Colombo A; Morel MA; Feldman TE; Holmes DR; Mack MJ; Morice MC; Kappetein AP; Palmerini T; Stone GW; Serruys PW
    Am J Cardiol; 2015 Jul; 116(2):174-86. PubMed ID: 25983123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
    Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
    Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Impact of Residual Anatomic Disease Burden After Functionally Complete Revascularization.
    Lee JM; Hwang D; Choi KH; Lee HJ; Song YB; Cho YK; Nam CW; Hahn JY; Shin ES; Doh JH; Hoshino M; Hamaya R; Kanaji Y; Murai T; Zhang JJ; Ye F; Li X; Ge Z; Chen SL; Kakuta T; Koo BK
    Circ Cardiovasc Interv; 2020 Sep; 13(9):e009232. PubMed ID: 32895005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objectifying the level of incomplete revascularization by the residual SYNTAX score and evaluating its impact on the one-year outcome of percutaneous coronary intervention in patients with multi-vessel disease.
    Alidoosti M; Saroukhani S; Lotfi-Tokaldany M; Jalali A; Sobh-Rakhshankhah A
    Cardiovasc Revasc Med; 2016; 17(5):308-12. PubMed ID: 27198530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents.
    Panoulas VF; Latib A; Naim C; Sato K; Ielasi A; Tespili M; Godino C; Testa L; Bedogni F; Colombo A
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1168-76. PubMed ID: 26269415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.